• Neurology · Jul 1988

    Treating multiple sclerosis with monoclonal antibodies: the cons.

    • R E Champlin.
    • Department of Medicine, UCLA School of Medicine 90024.
    • Neurology. 1988 Jul 1;38(7 Suppl 2):47-9.

    AbstractThe clinical use of monoclonal antibodies (MAbs) in multiple sclerosis (MS) is an exciting clinical prospect whose current use is subject to several limitations. Clinical studies to date have shown that infusion of murine MAbs, the preparations presently available, is associated with the production of antimurine antibody, which makes the long-term use of this therapy infeasible in most patients. This is a considerable drawback in a chronic progressive disease such as MS, where retreatment options are an important consideration in choice of therapy. In addition, most murine MAbs are not lytic for targeted cells. The target antigens often undergo modulation and the cells reappear in the circulation with full function in spite of ongoing therapy. The use of MAbs in MS needs further clarification through randomized, controlled clinical trials.

      Pubmed     Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…